Cord and adult blood platelets are an invaluable resource which is generously donated and, in most cases, discarded – there is nothing more noble than providing the means to repurpose discarded blood into advanced tissue regeneration therapeutic products for the treatment of the most fragile patients.
THE NEXT WAVE OF TISSUE REGENERATION
Building on the experience of the BioNest systems WhiteNest in working on the next generation of innovative tissue regeneration pharmaceuticals finding applications in dermatology, ophthalmology, dentistry, orthopedics and beyond.
JULY 2008
PATENT ON PLATELET FRACTION FROM UMBILICAL CORD BLOOD
Umbilical cord blood platelets contain unique immunomodulatory and tissue regenerative factors which play a critical role wound healing.
Patents: Italy n.1 392 897; Europe no. EP 2 304 023B1; USA no. US 8,501,170 B2.
JUNE 2015
INTRODUCTION OF THE BIONEST SYSTEMS
The patenting of the BioNest System has advanced the production and administration of cord blood components. This system ensures a safer and more effective manufacturing of Platelets, Plasma, and Red Blood Cells, with the potential of enhancing patient care in blood transfusion and in tissue regenerative therapies.
Patents: Europe no. EP 4 061 444A0 and EP 3302601B1.
NOVEMBER 2019
PLATELET LYSATE LYOPHILISATION
This pioneering R&D project aimed to standardize production, improve stability and extend shelf life of cord blood and adult donor blood platelet lysate, setting the stage to globally distribute Lysarderm, a dermatological cream for patients with diabetic foot ulcers.
MAY 2020
NEOFASTER BIO: FIRST BATCH PRODUCTION
The production of the first batch of lyophilised cord blood platelet lysate, branded as NeoFaster Bio, represented a significant achievement. NeoFaster Bio is positioned as a key starting material in the development of advanced regenerative therapies.
MARCH 2023
STABILITY MILESTONE FOR NEOFASTER BIO
NeoFaster Bio achieved a landmark stability of 2 years in the first round of stability testing — Underscores the product’s potential in providing long-term, effective solutions for regenerative treatments.
APRIL 2023
EMA REGISTRATION OF LYOPHILISED PLATELET EXTRACT
WhiteNest Pharma became the first pharmaceutical company to register a lyophilised platelet extract in the EMA product list – offering new hope for diabetic foot ulcer patients worldwide.
NOVEMBER 2023
VALIDATION OF CORD BLOOD COMPONENTS PRODUCTION
Following rigorous testing, a standardized procedure for the production of cord blood components with the BioNest System was validated by the international collaborative MultiCord12 focus group (Blood Transfus. 2023 Nov 3;21(6):526-537).
APRIL 2024
LYSADERM PHARMACEUTICAL DEVELOPMENT PROGRAM
The submission of Lysaderm’s pharmaceutical development program to the EMA for scientific advice is a critical step forward towards developing clinical trials and bringing this innovative treatment to patients globally.
BLOOD BANKING
Prof. Paolo Rebulla, our co-founder, pioneered a transformative concept in cord blood banking. Moving beyond the narrow focus on buffy coat storage, this innovative approach harnesses the full potential of all blood components. This shift not only minimizes waste but also expands therapeutic possibilities in public hospitals and pharmaceutical applications, setting a new standard in the field.
